Expression of CCL17 and CCL22 by latent membrane protein 1-positive tumor cells in age-related Epstein-Barr virus-associated B-cell lymphoproliferative disorder

Cancer Science

Volumn 99, Issue 2, 2008, Pages 296-302

  Takegawa, Sumio ^a   Jin, Zhe ^a   Nakayama, Takashi ^a   Oyama, Takashi ^b   Hieshima, Kunio ^a   Nagakubo, Daisuke ^a   Shirakawa, Aiko Konno ^a   Tsuzuki, Toyonori ^b   Nakamura, Shigeo ^c   Yoshie, Osamu ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CCL22 CHEMOKINE; CHEMOKINE; CHEMOKINE RECEPTOR CCR4; FORKHEAD TRANSCRIPTION FACTOR; LATENT MEMBRANE PROTEIN 1; THYMUS AND ACTIVATION REGULATED CHEMOKINE; UNCLASSIFIED DRUG;

ADULT; AGE RELATED EPSTEIN BARR VIRUS ASSOCIATED LYMPHOPROLIFERATIVE DISEASE; AGED; ARTICLE; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LYMPHOPROLIFERATIVE DISEASE; MALE; PATHOGENESIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TUMOR CELL;

B-LYMPHOCYTES; CHEMOKINE CCL17; CHEMOKINE CCL22; FORKHEAD TRANSCRIPTION FACTORS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOPROLIFERATIVE DISORDERS; TUMOR CELLS, CULTURED; VIRAL MATRIX PROTEINS;

EID: 38949204882     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00687.x     Document Type: Article

References (34)

1. Thompson MP, Kurzrock R. Epstein-Barr virus and cancer. Clin Cancer Res 2004; 10: 803-21.
2. + B-cell lymphoproliferative disorders: A clinicopathologic study of 22 patients. Am J Surg Pathol 2003; 27: 16-26.
3. Oyama T, Yamamoto K, Asano N et al. Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: A study of 96 patients. Clin Cancer Res 2007; 13: 5124-32.
4. Park S, Lee J, Ko YH et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood 2007; 110: 972-8.
5. Haluska FG, Brufsky AM, Canellos GP. The cellular biology of the Reed-Sternberg cell. Blood 1994; 84: 1005-19.
6. Brauninger A, Schmitz R, Bechtel D, Renne C, Hansmann ML, Kuppers R. Molecular biology of Hodgkin's and Reed/Sternberg cells in Hodgkin's lymphoma. Int J Cancer 2006; 118: 1853-61.
7. Kuppers R, Rajewsky K. The origin of Hodgkin and Reed/Sternberg cells in Hodgkin's disease. Annu Rev Immunol 1998; 16: 471-93.
8. Schwering I, Brauninger A, Klein U et al. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2003; 101: 1505-12.
9. Hanamoto H, Nakayama T, Miyazato H et al. Expression of CCL28 by Reed-Sternberg cells defines a major subtype of classical Hodgkin's disease with frequent infiltration of eosinophils and/or plasma cells. Am J Pathol 2004; 164: 997-1006.
10. Hedvat CV, Jaffe ES, Qin J et al. Macrophage-derived chemokine expression in classical Hodgkin's lymphoma: Application of tissue microarrays. Mod Pathol 2001; 14: 1270-6.
11. Maggio EM, Van Den Berg A, Visser L et al. Common and differential chemokine expression patterns in rs cells of NLP, EBV positive and negative classical Hodgkin lymphomas. Int J Cancer 2002; 99: 665-72.
12. Teruya-Feldstein J, Jaffe ES, Burd PR, Kingma DW, Setsuda JE, Tosato G. Differential chemokine expression in tissues involved by Hodgkin's disease: Direct correlation of eotaxin expression and tissue eosinophilia. Blood 1999; 93: 2463-70.
13. van den Berg A, Visser L, Poppema S. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma. Am J Pathol 1999; 154: 1685-91.
14. +) regulatory T cells. J Exp Med 2001; 194: 847-53.
15. Yoshie O, Imai T, Nomiyama H. Chemokines in immunity. Adv Immunol 2001; 78: 57-110.
16. Marshall NA, Christie LE, Munro LR et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004; 103: 1755-62.
17. Alvaro T, Lejeune M, Salvado MT et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 2005; 11: 1467-73.
18. Ishida T, Ishii T, Inagaki A et al. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res 2006; 66: 5716-22.
19. Poppema S, van den Berg A. Interaction between host T cells and Reed-Sternberg cells in Hodgkin lymphomas. Semin Cancer Biol 2000; 10: 345-50.
20. Nakayama T, Hieshima K, Nagakubo D et al. Selective induction of Th2-attracting chemokines CCL17 and CCL22 in human B cells by latent membrane protein 1 of Epstein-Barr virus. J Virol 2004; 78: 1665-74.
21. Brink AA, Dukers DF, van den Brule AJ et al. Presence of Epstein-Barr virus latency type III at the single cell level in post-transplantation lymphoproliferative disorders and AIDS related lymphomas. J Clin Pathol 1997; 50: 911-18.
22. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057-61.
23. Lan HY, Mu W, Nikolic-Paterson DJ, Atkins RC. A novel, simple, reliable, and sensitive method for multiple immunoenzyme staining: Use of microwave oven heating to block antibody crossreactivity and retrieve antigens. J Histochem Cytochem 1995; 43: 97-102.
24. Lim HW, Hillsamer P, Kim CH. Regulatory T cells can migrate to follicles upon T cell activation and suppress GC-Th cells and GC-Th cell-driven B cell responses. J Clin Invest 2004; 114: 1640-9.
25. + regulatory T cells during acute graft-versus-host disease. Blood 2005; 106: 3300-7.
26. Valmori D, Merlo A, Souleimanian NE, Hesdorffer CS, Ayyoub M. A peripheral circulating compartment of natural naive CD4 Tregs. J Clin Invest 2005; 115: 1953-62.
27. Lim HW, Broxmeyer HE, Kim CH. Regulation of trafficking receptor expression in human forkhead box P3+ regulatory T cells. J Immunol 2006; 177: 840-51.
28. Hopwood P, Crawford DH. The role of EBV in post-transplant malignancies: a review. J Clin Pathol 2000; 53: 248-54.
29. Chetty R, Biddolph S, Gatter K. An immunohistochemical analysis of Reed-Sternberg-like cells in posttransplantation lymphoproliferative disorders: The possible pathogenetic relationship to Reed-Sternberg cells in Hodgkin's disease and Reed-Sternberg-like cells in non-Hodgkin's lymphomas and reactive conditions. Hum Pathol 1997; 28: 493-8.
30. Glaser SL, Dorfman RF, Clarke CA. Expert review of the diagnosis and histologic classification of Hodgkin disease in a population-based cancer registry: Interobserver reliability and impact on incidence and survival rates. Cancer 2001; 92: 218-24.
31. Jarrett RF, Krajewski AS, Angus B et al. The Scotland and Newcastle epidemiological study of Hodgkin's disease: Impact of histopathological review and EBV status on incidence estimates. J Clin Pathol 2003; 56: 811-16.
32. Bargou RC, Emmerich F, Krappmann D et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 1997; 100: 2961-9.
33. Baldwin AS Jr. The NF-kappa B and I kappa B proteins: New discoveries and insights. Annu Rev Immunol 1996; 14: 649-83.
34. Kaye KM, Devergne O, Harada JN et al. Tumor necrosis factor receptor associated factor 2 is a mediator of NF-kappa B activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein. Proc Natl Acad Sci USA 1996; 93: 11085-90.